Hager Alicia J.
Chief Legal Officer at NKTX; SVP & General Counsel at OncoMed Pharmaceuticals Inc
- Sold, on record
- $587k
- Dollars the filings state
- Form 4 sales
- 19
- Latest Jan 15, 2025
- Form 144 notices
- 1
- Proposed sales
- Companies
- 2
- Filed as an executive or holder
Companies
- NKTXNkarta, Inc.Chief Legal Officer
- OncoMed Pharmaceuticals IncSVP & General Counsel
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- OncoMed Pharmaceuticals Inc35,132 shares
- NKTX20,065 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale OncoMed Pharmaceuticals IncPlan not statedOct 10, 2018 2018
Sold 1,156 shares at $2.02 ($2k)
Hager Alicia J., SVP & General Counsel
Sold 2.2% of holdings ($107k position)51,754 shares left0.3x usual sizeFiling
- 2 Form 4 sale NKTXPlan not statedJan 17, 2023 +1560 days
Sold 1,103 shares at $5.49 ($6k)
Hager Alicia J., Chief Legal Officer
Sold 1.9% of holdings ($320k position)57,197 shares leftFirst sale on recordFiling
- 3 Form 4 sale NKTXNo planJun 20, 2023 +154 days
Sold 701 shares at $4.85 ($3k)
Hager Alicia J., Chief Legal Officer
No 10b5-1 planSold 1.2% of holdings ($277k position)56,496 shares leftFiling
- 4 Form 4 sale NKTXNo planJan 16, 2024 +210 days
Sold 4,554 shares at $8.74 ($40k)
Hager Alicia J., Chief Legal Officer
No 10b5-1 planSold 4% of holdings ($983k position)107,942 shares leftFiling
- 5 Form 4 sale NKTXNo planJun 18, 2024 +154 days
Sold 727 shares at $5.60 ($4k)
Hager Alicia J., Chief Legal Officer
No 10b5-1 planSold 0.7% of holdings ($604k position)107,215 shares left0.7x usual sizeFiling
- 6 Form 144 notice NKTXNoticeJul 16, 2024 +28 days
Filed to sell 3,396 shares ($24k)
Hager Alicia J., Officer
10b5-1 plan3.7x usual sizeFiling
- 7 Form 4 sale NKTXUnusualJul 16, 2024 same day
Sold 3,396 shares at $8.00 ($27k)
Hager Alicia J., Chief Legal Officer
10b5-1 planSold 3.2% of holdings ($858k position)103,819 shares left3.7x usual sizeFollows a Form 144Filing
- 8 Form 4 sale NKTXUnusualJan 15, 2025 +183 days
Sold 9,584 shares at $2.20 ($21k)
Hager Alicia J., Chief Legal Officer
No 10b5-1 planSold 6.1% of holdings ($344k position)146,735 shares left8.7x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (20)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Jan 15, 2025 | Jan 17, 2025 | NKTX | Chief Legal Officer | Form 4 sale | 9,584 | $21k | 6.1% | Unusual | SEC |
| Jul 16, 2024 | Jul 18, 2024 | NKTX | Chief Legal Officer | Form 4 sale | 3,396 | $27k | 3.2% | Unusual | SEC |
| Jul 16, 2024 | Jul 16, 2024 | NKTX | Officer | Form 144 notice | 3,396 | $24k | Notice | SEC | |
| Jun 18, 2024 | Jun 20, 2024 | NKTX | Chief Legal Officer | Form 4 sale | 727 | $4k | 0.7% | No plan | SEC |
| Jan 16, 2024 | Jan 18, 2024 | NKTX | Chief Legal Officer | Form 4 sale | 4,554 | $40k | 4.0% | No plan | SEC |
| Jun 20, 2023 | Jun 22, 2023 | NKTX | Chief Legal Officer | Form 4 sale | 701 | $3k | 1.2% | No plan | SEC |
| Jan 17, 2023 | Jan 18, 2023 | NKTX | Chief Legal Officer | Form 4 sale | 1,103 | $6k | 1.9% | Plan not stated | SEC |
| Oct 10, 2018 | Oct 11, 2018 | OncoMed Pharmaceuticals Inc | SVP & General Counsel | Form 4 sale | 1,156 | $2k | 2.2% | Plan not stated | SEC |
| Oct 9, 2018 | Oct 10, 2018 | OncoMed Pharmaceuticals Inc | SVP & General Counsel | Form 4 sale | 1,686 | $4k | 3.1% | Plan not stated | SEC |
| Apr 24, 2018 | Apr 26, 2018 | OncoMed Pharmaceuticals Inc | SVP & General Counsel | Form 4 sale | 4,051 | $11k | 6.9% | Plan not stated | SEC |
| Oct 10, 2017 | Oct 12, 2017 | OncoMed Pharmaceuticals Inc | SVP & General Counsel | Form 4 sale | 1,248 | $5k | 2.1% | Plan not stated | SEC |
| Apr 4, 2017 | Apr 5, 2017 | OncoMed Pharmaceuticals Inc | SVP & General Counsel | Form 4 sale | 4,316 | $39k | 16.7% | Plan not stated | SEC |
| Mar 15, 2017 | Mar 17, 2017 | OncoMed Pharmaceuticals Inc | SVP & General Counsel | Form 4 sale | 6,652 | $67k | 20.4% | Unusual | SEC |
| Jan 7, 2016 | Jan 8, 2016 | OncoMed Pharmaceuticals Inc | VP & General Counsel | Form 4 sale | 1,623 | $36k | 10.8% | Plan not stated | SEC |
| Nov 27, 2015 | Dec 1, 2015 | OncoMed Pharmaceuticals Inc | VP & General Counsel | Form 4 sale | 1,800 | $42k | 10.7% | Plan not stated | SEC |
| Oct 27, 2015 | Oct 29, 2015 | OncoMed Pharmaceuticals Inc | VP & General Counsel | Form 4 sale | 5,400 | $113k | 26.5% | Unusual | SEC |
| Jul 28, 2015 | Jul 29, 2015 | OncoMed Pharmaceuticals Inc | VP & General Counsel | Form 4 sale | 1,800 | $38k | 10.7% | Plan not stated | SEC |
| Jun 29, 2015 | Jun 30, 2015 | OncoMed Pharmaceuticals Inc | VP & General Counsel | Form 4 sale | 1,800 | $41k | 10.7% | Plan not stated | SEC |
| May 27, 2015 | May 28, 2015 | OncoMed Pharmaceuticals Inc | VP & General Counsel | Form 4 sale | 1,800 | $42k | 10.7% | Plan not stated | SEC |
| Apr 27, 2015 | Apr 29, 2015 | OncoMed Pharmaceuticals Inc | VP & General Counsel | Form 4 sale | 1,800 | $46k | 10.7% | Plan not stated | SEC |